170 related articles for article (PubMed ID: 2503225)
21. Effects of encainide on the determinants of cardiac excitability in sheep Purkinje fibers.
Arnsdorf MF; Schmidt GA; Sawicki GJ
J Pharmacol Exp Ther; 1985 Jan; 232(1):40-8. PubMed ID: 3917508
[TBL] [Abstract][Full Text] [Related]
22. Rate-dependent depression of maximal rate of depolarization in guinea pig papillary muscle action potentials by changrolin.
Kuang Y; Liu TP
Zhongguo Yao Li Xue Bao; 1990 May; 11(3):225-9. PubMed ID: 2087995
[TBL] [Abstract][Full Text] [Related]
23. Cellular electrophysiological properties of a new aminosteroid antiarrhythmic agent, SC-35135.
Borowicz LE; Martin CL; Sanguinetti MC
J Cardiovasc Pharmacol; 1988 Aug; 12(2):218-26. PubMed ID: 2459553
[TBL] [Abstract][Full Text] [Related]
24. Use-dependent actions and effects on transmembrane action potentials of flecainide, encainide, and ethmozine in canine Purkinje fibers.
Lee JH; Rosen MR
J Cardiovasc Pharmacol; 1991 Aug; 18(2):285-92. PubMed ID: 1717791
[TBL] [Abstract][Full Text] [Related]
25. Selective depression of conduction of premature action potentials in canine Purkinje fibres by class Ib antiarrhythmic drugs: comparison with Ia and Ic drugs.
Pallandi RT; Campbell TJ
Cardiovasc Res; 1988 Mar; 22(3):171-8. PubMed ID: 3167941
[TBL] [Abstract][Full Text] [Related]
26. Electrophysiologic effects of encainide (MJ 9067) on canine Purkinje fibres.
Gibson JK; Somani P; Bassett AL
Eur J Pharmacol; 1978 Nov; 52(2):161-9. PubMed ID: 729630
[No Abstract] [Full Text] [Related]
27. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations.
McAllister CB; Wolfenden HT; Aslanian WS; Woosley RL; Wilkinson GR
Xenobiotica; 1986 May; 16(5):483-90. PubMed ID: 3090789
[TBL] [Abstract][Full Text] [Related]
28. Importance of physico-chemical properties in determining the kinetics of the effects of Class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle.
Campbell TJ
Br J Pharmacol; 1983 Sep; 80(1):33-40. PubMed ID: 6652373
[TBL] [Abstract][Full Text] [Related]
29. Electrophysiologic effects of detajmium on isolated dog cardiac ventricular and Purkinje fibers.
Hála O; Németh M; Varró A; Papp JG
J Cardiovasc Pharmacol; 1994 Oct; 24(4):559-65. PubMed ID: 7528838
[TBL] [Abstract][Full Text] [Related]
30. Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.
Davy JM; Dorian P; Kantelip JP; Harrison DC; Kates RE
J Pharmacol Exp Ther; 1986 Jun; 237(3):907-11. PubMed ID: 3086540
[TBL] [Abstract][Full Text] [Related]
31. Metabolite cumulation during long-term oral encainide administration.
Kates RE; Harrison DC; Winkle RA
Clin Pharmacol Ther; 1982 Apr; 31(4):427-32. PubMed ID: 6800679
[TBL] [Abstract][Full Text] [Related]
32. Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers.
Elharrar V; Zipes DP
J Pharmacol Exp Ther; 1982 Feb; 220(2):440-7. PubMed ID: 6799644
[No Abstract] [Full Text] [Related]
33. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification.
Campbell TJ
Cardiovasc Res; 1983 Jun; 17(6):344-52. PubMed ID: 6883410
[TBL] [Abstract][Full Text] [Related]
34. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs.
Kerr MJ; Allen JD; Harron DW; Shanks RG
J Cardiovasc Pharmacol; 1985; 7(3):449-57. PubMed ID: 2410673
[TBL] [Abstract][Full Text] [Related]
35. Effects of encainide and its metabolites on energy requirements for defibrillation.
Fain ES; Dorian P; Davy JM; Kates RE; Winkle RA
Circulation; 1986 Jun; 73(6):1334-41. PubMed ID: 3084128
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and metabolism of encainide.
Jaillon P
Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833
[TBL] [Abstract][Full Text] [Related]
37. Encainide.
Antonaccio MJ; Gomoll AW; Byrne JE
Cardiovasc Drugs Ther; 1989 Oct; 3(5):691-710. PubMed ID: 2518680
[TBL] [Abstract][Full Text] [Related]
38. Electrophysiological actions of BRB-I-28 in canine myocardial tissues.
Patterson E; Scherlag BJ; Berlin KD; Lazzara R
J Pharmacol Exp Ther; 1991 Nov; 259(2):558-65. PubMed ID: 1941607
[TBL] [Abstract][Full Text] [Related]
39. Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.
Fleming JS; Buchanan JO; Yocca FD; Iben LG; Antonaccio MJ
Cardiovasc Drugs Ther; 1991 Aug; 5(4):763-8. PubMed ID: 1909560
[TBL] [Abstract][Full Text] [Related]
40. Relationship between use-dependent effects of antiarrhythmic drugs on conduction and Vmax in canine cardiac Purkinje fibers.
Nattel S
J Pharmacol Exp Ther; 1987 Apr; 241(1):282-8. PubMed ID: 3572790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
